News and Trends 8 Nov 2022 Does covid vaccination boost cancer treatment? Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. It was feared that vaccination against Covid-19 could reduce the success of cancer treatment or cause severe side effects. However, a recent study by the universities of Bonn, Germany, and Shanxi, China, say this isn’t the case. According […] November 8, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Nov 2022 First patient dose completed for bladder cancer diagnostic drug Asieris Pharmaceuticals says it has completed the first patient dose in its phase III bridging trial for Hexvix, a drug used for the diagnosis of bladder cancer. Asieris Pharmaceuticals is a global biopharmaceutical company specializing in the discovery and development of drugs for the treatment of genitourinary tumors and other major diseases. The study is a […] November 7, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 4 Nov 2022Beyond Biotech podcast 21: CanSinoBIO, HTID, Longevity Science Foundation This week, we have three interviews, and four guests. We chat with Pierre Corneille VP of the HTFC, which is responsible for HealthTech Innovation Days; Sergey Jakimov, co-founder and managing partner of LongeVC and the Longevity Science Foundation’s CEO Lisa Ireland; and Pierre Morgon, executive vice president of CanSinoBIO. We also have our weekly contribution […] November 4, 2022 Share WhatsApp Twitter Linkedin Email
News and Trends 4 Nov 2022 Companies with exclusive rights to CRISPR diagnostic methods sign agreement Two companies with sole rights to two CRISPR diagnostic methods in markets outside the U.S. and Greater China have signed a licensing agreement. Sherlock Biosciences announced today (November 3) that it has signed a deal with China-based Tolo Biotech which grants co-exclusive rights to the Cas12 and Cas13 method patents. As the only two companies […] November 4, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 19 Oct 2022 Report says 20% of global cancer deaths could be avoided A new study by members of the Bloomberg New Economy International Cancer Coalition says at least 1.5 million deaths from cancer could be avoided each year. This is 20% of the annual global deaths resulting from cancer. The study says this could happen if international regulations around patient trials were more standardized and people placed […] October 19, 2022 - 6 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 17 Oct 2022 Clinical trial of treatment for advanced solid tumors approved A clinical trial of a drug to treat advanced solid tumors has been approved by the National Medical Products Administration. China-based Akeso Inc., made the announcement on Sunday (October 16) about a phase 1b/2 clinical trial of its in-house developed Ivonescimab (PD-1/VEGF bi-specific AK112) combined with Drebuxelimab (CD73, AK119). AK112 is the first PD-1/VEGF bi-specific […] October 17, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 13 Oct 2022 Merck contributing to Jacobio Pharma colorectal cancer clinical trial Jacobio announced it has entered into a clinical trial collaboration agreement with Merck on a clinical study of combination therapy between Jacobio’s KRAS G12C inhibitor JAB-21822 and Merck’s epidermal growth factor receptor (EGFR) inhibitor Erbitux (cetuximab). This clinical study aims to evaluate the efficacy of JAB-21822 in combination with cetuximab in patients with KRAS G12C-mutated […] October 13, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Oct 2022 Agreement signed to advance therapy for autoimmune disease HanAll Biopharma’s licensed partner, Harbour BioMed, has signed an exclusive sublicense agreement with CSPC NBP Pharmaceutical Co., Ltd for an advanced inhibitor. The agreement is for HanAll’s neonatal Fc receptor (FcRn) inhibitor batoclimab which is one of the most advanced being developed in Greater China. The companies say it has the potential to become a […] October 12, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 12 Oct 2022 WuXi Biologics and Toregem BioPharma to develop antibody for adentia treatment WuXi Biologics and Toregem BioPharma, a biotech startup company from Kyoto University, have signed a memorandum of understanding to form a strategic partnership to develop TRG035. TRG035 is a monoclonal antibody targeting USAG-1 as a tooth regeneration treatment for congenital adentia. Within the partnership, Toregem BioPharma will have access to WuXi Biologics’ integrated CMC services […] October 12, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 11 Oct 2022 The biggest private biotech investments in September 2022 The companies Acelyrin, InnovaFeed and Arsenal Biosciences bagged the biggest biotech investments in September 2022, with insect protein and cell therapies attracting big funding rounds. Autumn is in full swing in the Northern Hemisphere. After a breather in August 2022, September saw the return of big fundraising activity for biotech companies. We’ve gathered the biggest […] October 11, 2022 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 10 Oct 2022 JW Therapeutics receives approval for relapsed or refractory follicular lymphoma drug China’s National Medical Products Administration (NMPA) has approved the supplemental new drug application (sNDA) for JW Therapeutics’ anti-CD19 autologous chimeric antigen receptor T (CAR-T) cell immunotherapy product relmacabtagene autoleucel injection. Also known as relma-cel, the product has the trade name Carteyva. It is used for the treatment of adult patients with follicular lymphoma that is […] October 10, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 10 Oct 2022 Trial starts for treatment of warm autoimmune hemolytic anemia China-based Hutchmed has started a phase 2/3 trial of sovleplenib in adults with a disorder called warm antibody autoimmune hemolytic anemia (wAIHA). The autoimmune disorder can lead to anemia and currently has limited treatment options. It causes premature destruction of healthy red blood cells and the rate of production of new cells in the bone […] October 10, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email